Halozyme
HALO · Biotechnology
$125.63
0.9%Harmony Biosciences
HRMY · Biotechnology
$36.13
0.3%The short version
- Halozyme is the larger business, with $1.4B of revenue in fiscal 2025 against $869M for Harmony Biosciences, about 1.6 times as much.
- Halozyme grew revenue faster (37.6%, against 21.5%).
- Halozyme kept more of each dollar of sales as operating profit (33.6% operating margin, against 24.0% operating margin).
- Halozyme turned more of its sales into free cash flow (46.2% FCF margin, against 40.1% FCF margin).
- Harmony Biosciences earned a higher return on the capital invested in it (48.9%, against 19.2%).
- Investors pay more for each dollar of Halozyme’s earnings: a P/E of 36.6x against 11.7x for Harmony Biosciences.
| Latest fiscal year | HALO · FY25 | HRMY · FY25 |
|---|---|---|
| Size | ||
| Market cap | $15.2B | $2.1B |
| Revenue | $1.4B | $869M |
| Free cash flow | $645M | $348M |
| Net income | $317M | $159M |
| Growth | ||
| Revenue growth | 37.6% | 21.5% |
| 5-year growth | 39.2% | 40.3% |
| Share count change | −4.3% | 1.2% |
| Profitability | ||
| Gross margin | 83.6% | 77.2% |
| Operating margin | 33.6% | 24.0% |
| Net margin | 22.7% | 18.3% |
| FCF margin | 46.2% | 40.1% |
| Return on capital | 19.2% | 48.9% |
| Return on equity | 153.6% | 20.8% |
| Balance sheet | ||
| Net debt | $2.0B | −$612M |
| Net debt / EBITDA | 4.2x | — |
| Dividends and buybacks | $342M | $0.0M |
| Valuation & quality | ||
| P/E | 36.6x | 11.7x |
| Piotroski F-score | 5 | 5 |
FY16
HALO $147M
HRMY —
FY17
HALO $317M
HRMY —
FY18
HALO $152M
HRMY —
FY19
HALO $196M
HRMY $6.0M
FY20
HALO $268M
HRMY $160M
FY21
HALO $443M
HRMY $305M
FY22
HALO $660M
HRMY $438M
FY23
HALO $829M
HRMY $582M
FY24
HALO $1.0B
HRMY $715M
FY25
HALO $1.4B
HRMY $869M
HALO
HRMY
FY16
HALO −56.7%
HRMY —
FY17
HALO 25.6%
HRMY —
FY18
HALO −45.7%
HRMY —
FY19
HALO −34.5%
HRMY −2,433.8%
FY20
HALO 53.9%
HRMY 10.6%
FY21
HALO 62.2%
HRMY 28.7%
FY22
HALO 40.5%
HRMY 27.5%
FY23
HALO 40.7%
HRMY 33.0%
FY24
HALO 54.3%
HRMY 26.7%
FY25
HALO 33.6%
HRMY 24.0%
HALO
HRMY
FY16
HALO −$53.5M
HRMY —
FY17
HALO $133M
HRMY —
FY18
HALO −$54.2M
HRMY —
FY19
HALO −$89.5M
HRMY −$75.6M
FY20
HALO $53.0M
HRMY −$3.0M
FY21
HALO $298M
HRMY $98.3M
FY22
HALO $235M
HRMY $144M
FY23
HALO $373M
HRMY $219M
FY24
HALO $468M
HRMY $219M
FY25
HALO $645M
HRMY $348M
HALO
HRMY
FY16
HALO −103.0%
HRMY —
FY17
HALO 61.2%
HRMY —
FY18
HALO −28.1%
HRMY —
FY19
HALO −38.2%
HRMY —
FY20
HALO —
HRMY —
FY21
HALO —
HRMY 78.2%
FY22
HALO 27.9%
HRMY 57.8%
FY23
HALO 21.3%
HRMY 49.3%
FY24
HALO 34.9%
HRMY 42.7%
FY25
HALO 19.2%
HRMY 48.9%
HALO
HRMY
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.